Full Press Release Details
Names Cellectis on Annual List of 50 Smartest Companies for Second
NEW YORK--(BUSINESS WIRE)--June 27, 2016--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS),
a biopharmaceutical company focused on developing immunotherapies based
on gene edited CAR T-cells (UCART), today announced that MIT
Technology Review has named the Company on its Annual List of 50
Smartest Companies for the second year in a row. This prestigious list
recognizes and celebrates companies that combine innovative technology
with an effective and ambitious business model. Each year, the outlet
identifies 50 companies that are considered smart in the ways that they
create new opportunities.
MIT Technology Review listed immune engineering as one of its 10
Breakthrough Technologies of 2016, a field that Cellectis has continued
to shape and impact via the Company's development and therapeutic
application of allogeneic CAR T-cell immunotherapies targeting cancer.
In this process, T-cells from healthy donors are genetically edited with
Cellectis' proprietary TALEN technology to seek and destroy cancer
In late 2015 and early 2016, two groundbreaking compassionate care cases
have been reported with UCART19, an "off-the-shelf" gene edited T-cell
product that has been designed and manufactured by Cellectis. What's
more is that earlier this month, Cellectis also announced that the first
patient has been dosed in a Phase I UCART19 study for Leukemia.
"We are honored that MIT Technology Review has once again
selected Cellectis for this award and it is truly gratifying to be
recognized among such innovative and pioneering industry leaders," said
Dr. Andr Choulika, Chairman and Chief Executive Officer of Cellectis.
"At Cellectis, we make it our mission to not only push the boundaries
for what's possible in the global healthcare and life sciences spaces
but also work to redefine what standard cancer treatment looks like for
patients in need all over the world."
Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART). The company's
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 16 years of expertise
in genome engineering - based on its flagship TALEN
products and meganucleases and pioneering electroporation PulseAgile
technology - to create a new generation of immunotherapies. CAR
technologies are designed to target surface antigens expressed on cells.
Using its life-science-focused, pioneering genome-engineering
technologies, Cellectis' goal is to create innovative products in
multiple fields and with various target markets. Cellectis is listed on
the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market
(ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it.
TALEN is a registered
trademark owned by the Cellectis Group.
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company's
objectives based on the current expectations and assumptions of the
Company's management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.
VP of Communications
Kasunich, 212-896-1241
KCSA Strategic Communications
Harnest, 646-385-9008
VP of Corporate Strategy and Finance